Industry Observation I Inventory of Improved New Drugs Entering Medical Insurance through Negotiation
Click:263  Update time:2023-06-02  【Close

We searched the 2023 version of the medical insurance catalog and sorted out the improved new drugs in the negotiated drugs during the agreement period. A total of 9 representative varieties were collected and analyzed through incomplete statistics.

Serial Number Breed Enterprise Indication Approve time Agreement period
1 Hydrochloric acid memantine oral solution film Qilu Alzheimer 2022 March 1st, 2023 to December 31st, 2024
2 Ondansetron mouth dissolving film Hengrui Antiemetic 2022 March 1, 2023 to December 31, 2024
3 Olanzapine oral solution film Qilu/Hausen Schizophrenia



March 1, 2023 to December 31, 2024
4 Liluzole oral suspension ITALFARMACO, S.A. Amyotrophic lateral sclerosis of spinal cord 2022 March 1, 2023 to December 31, 2024
5 Acetate octreotide microspheres for injection Novartis Pharma Acromegaly; Gastrointestinal and pancreatic endocrine tumors 2003 March 1, 2023 to December 31, 2024
6 Risperidone microspheres for injection Green leaf Clear positive symptoms for the treatment of acute and chronic schizophrenia, as well as various other psychiatric states 2021 March 1, 2023 to December 31, 2024
7 Paclitaxel liposomes for injection Green leaf It can be used for first-line chemotherapy of ovarian cancer and subsequent treatment of ovarian metastatic cancer, as first-line chemotherapy, and can be combined with cisplatin; It can also be used for the follow-up treatment of breast cancer patients who have used standard chemotherapy containing doxorubicin or the treatment of recurrent patients; 2021 March 1, 2023 to December 31, 2024
8 Clopidogrel aspirin tablets Sanofilepu Secondary Prevention of Atherosclerotic Thrombosis



March 1, 2023 to December 31, 2024
9 Sodium phosphate powder Sichuan Jianneng Preoperative intestinal cleaning 2021 March 1, 2023 to December 31, 2024

Oral membrane

Memantine hydrochloride oral solution film, olanzapine oral solution film and ondansetron oral solution film can be reviewed together. Oral dissolution film is a new type of oral drug delivery system that can be quickly dissolved and absorbed in the mouth without drinking water or chewing. In clinical practice, patients with difficulty in swallowing and taking medicine are often solved, such as migraine, central nervous system disease, etc. At present, there are only 6 approved varieties of oral film in China.

Serial Number Breed Enterprise
1 Montelukast sodium oral solution film Qilu
2 Tadalafil oral solution film Qilu
3 Aripiprazole oral solution film Qilu
4 Hydrochloric acid memantine oral solution film Qilu
Olanzapine oral solution film Qilu
Olanzapine oral solution film Hansoh
6 Ondansetron mouth dissolving film Hengrui

However, there are many registration applications and incomplete statistics. More than 10 varieties have been applied for clinical use, including desloratadine oral solution film, lurasidone oral solution film, dapoxetine oral solution film, oseltamivir phosphate oral solution film, risperidone oral solution film, epipiprazole oral solution film, brepiprazole oral solution film, ambroxol hydrochloride oral solution film, and donepezil hydrochloride oral solution film.

The medical insurance payment price for Meijingang oral dissolution film is 1.64 yuan/5mg/tablet and 2.78 yuan/10mg/tablet. The minimum amount of 10mg of regular Macadamant tablets for centralized purchase is 0.16 yuan/tablet/10mg, and the maximum amount is 1.15 yuan/tablet/10mg. Compared to regular tablets, the price of oral film is moderate.

The medical insurance payment prices for olanzapine oral dissolution film are 3.9 yuan/tablet/5mg and 6.63 yuan/tablet/10mg, respectively. It should be noted that this variety includes Qilu and Haosen, and this payment price is formed by bidding.

The payment price of ondansetron oral dissolution membrane is not shown in the medical insurance catalogue.

Liluzole oral suspension

Liluzole is available in both regular tablets and capsules on the domestic market. Ordinary tablets can be imported and domestically produced, while capsules can only be domestically produced. Oral suspension is administered through an oral syringe to solve the medication difficulties of ALS patients. The medical insurance payment price is 628 yuan (300ml: 1.5g/bottle). Adults take 100mg per day, 628 yuan per day for 15 days, and 41.9 yuan per day.

50mg regular tablets are imported for 55 yuan per tablet, and take 2 tablets per day for 100mg/110 yuan. Domestic 50mg regular tablets cost 17.9 yuan, around 35 yuan per day. So the advantages of oral suspension are evident. However, it may be inconvenient to use an oral syringe (for quantification).

In addition, the introduction and production of the Liluzole oral dissolution film introduced by Hisco have been announced, and the future will depend on how it is priced or what price it will be offered for medical insurance.

High end injection

The combination of acetic acid octreotide microspheres for injection, risperidone microspheres for injection, and paclitaxel liposomes for injection belongs to the category of high-end injections.
Risperidone microspheres and paclitaxel liposomes are both exclusive varieties of Green Leaf, while Octreotide acetate microspheres are from Novartis, which was approved for marketing early in 2003. Now Novartis has chosen to actively participate in medical insurance.
In addition, the payment prices for the above types of medical insurance are not displayed in the catalog.

Sodium phosphates oral solution

This variety has been approved as a Class 2.2 improved new drug, developed by Sichuan Jianneng, and is reported to be the world's first sodium phosphate powder.
At present, oral intestinal cleaning drugs include compound polyethylene glycol electrolyte powder, sodium phosphate oral solution, polyethylene glycol electrolyte oral solution, etc. In preparation for intestinal cleaning, if the patient takes an oral solution of sodium phosphate, the water intake is generally 1600ml, taking 800ml twice. When taking compound polyethylene glycol electrolyte powder, the patient's water intake is generally 3L. In addition, there are many cases of gastric and intestinal mucosal damage and instant severe electrolyte disorders caused by undiluted or insufficiently diluted sodium phosphate oral solution.
Sichuan Jianneng has its own oral solution of sodium phosphate, so it is most aware of the problems in clinical practice of sodium phosphate oral solution. Therefore, the development of improved new drugs is an iterative upgrade for itself.


Sometimes, the moat of improved new drugs is not so strong. After being launched, it is important to rely on the first mover advantage to promote rapid clinical volume. The payment side is an important factor in determining the volume, so it is particularly important to enter the medical insurance catalog as soon as possible after being launched. Forming medication habits in clinical practice can also become a competitive barrier for a variety.

Last:Industry Dynamics - USCB Lottigatin Patch Patent Appeal Rejected
Next:Industry observation - irreconcilable contradictions, American Chamber of Commerce sues HHS


Lindmik Pharmaceutical(Suzhou)Co.,Ltd is a high-tech pharmaceutical enterprise focusing on the research and development, production and sales of innovative pharmaceutical preparations.Equipped with a number of its own innovative R&D platform of dosage forms, including the transdermal drug delivery system, and at the same time, actively introducing the world’s leading nano-based drug delivery, microspheres drug delivery and other cutting-edge pharmaceutical technologies by means of “license in”, the company is a new rapidly developing company pharmaceutical companies that catches people’s eyes.




  • 12th Floor, Building 5, Tianyun Plaza, 111 Wusongjiang Avenue, Guoxiang Street, Wuzhong District, Suzhou City

  • 0512-66020899

  • 0512-66022699

  • 215124

© COPYRIGHT Lindmik Pharmaceutical(Suzhou)Co.,Ltd. All Rights Reserved